The Nm23-H1 metastasis suppressor as a translational target

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1278-1282

  Marshall, Jean Claude ^a   Collins, Joshua ^a   Marino, Natascia ^a   Steeg, Patricia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Metastasis; Nm23 H1

Indexed keywords

ACETYLSALICYLIC ACID; CELL SURFACE RECEPTOR; CYCLOPHOSPHAMIDE; LYSOPHOSPHATIDIC ACID; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; NANOPARTICLE; NUCLEOSIDE DIPHOSPHATE KINASE A; PARVOVIRUS VECTOR; PLASMID DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYLYSINE IRON OXIDE NANOPARTICLE; PROTEIN HISTIDINE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BONE DENSITY; BREAST CANCER; DOWN REGULATION; DRUG MEGADOSE; DRUG TARGETING; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; UPREGULATION; VIRAL GENE THERAPY; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; HUMANS; LYSOPHOSPHOLIPIDS; MEDROXYPROGESTERONE ACETATE; MICE; NEOPLASM METASTASIS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; TRANSLATIONAL RESEARCH;

EID: 77950595309     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.042     Document Type: Article

References (25)

1. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12 8 (2006) 895-904
2. Horak C.E., Lee J.H., Marshall J.C., Shreeve S.M., and Steeg P.S. The role of metastasis suppressor genes in metastatic dormancy. APMIS 116 7-8 (2008) 586-601
3. Steeg P.S., Horak C.E., and Miller K.D. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 14 16 (2008) 5006-5012
4. Steeg P.S., Bevilacqua G., Pozzatti R., Liotta L.A., and Sobel M.E. Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 48 22 (1988) 6550-6554
5. Besant P.G., and Attwood P.V. Mammalian histidine kinases. Biochim Biophys Acta 1754 1-2 (2005) 281-290
6. Steeg P.S., Palmieri D., Ouatas T., and Salerno M. Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. Cancer Lett 190 1 (2003) 1-12
7. Wagner P.D., Steeg P.S., and Vu N.D. Two-component kinase-like activity of nm23 correlates with its motility-suppressing activity. Proc Natl Acad Sci USA 94 17 (1997) 9000-9005
8. Slemmer J.E., Haasdijk E.D., Engel D.C., Plesnila N., and Weber J.T. Aldolase C-positive cerebellar Purkinje cells are resistant to delayed death after cerebral trauma and AMPA-mediated excitotoxicity. Eur J Neurosci 26 3 (2007) 649-656
9. Hartsough M.T., Morrison D.K., Salerno M., et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway. J Biol Chem 277 35 (2002) 32389-32399
10. Salerno M., Palmieri D., Bouadis A., Halverson D., and Steeg P.S. Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol 25 4 (2005) 1379-1388
11. Ouatas T., Halverson D., and Steeg P.S. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 9 10 Pt 1 (2003) 3763-3772
12. Palmieri D., Halverson D.O., Ouatas T., et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97 9 (2005) 632-642
13. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 1 (2002) 73-80
14. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 8 (2000) R15-R24
15. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 7 (2000) 1878-1886
16. Ushijima K., Yahata H., Yoshikawa H., et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 19 (2007) 2798-2803
17. Yamazawa K., Hirai M., Fujito A., et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22 7 (2007) 1953-1958
18. Li J., Zhou J., Chen G., et al. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther 13 3 (2006) 266-272
19. Li Z., Xiang J., Zhang W., et al. Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther 16 5 (2009) 423-429
20. Horak C.E., Lee J.H., Elkahloun A.G., et al. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 67 15 (2007) 7238-7246
21. Horak C.E., Mendoza A., Vega-Valle E., et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 67 24 (2007) 11751-11759
22. MacDonald N., Freije J., Stracke M., Manrow R., and Steeg P. Site directed mutagenesis of nm23-H1: mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem 271 (1996) 25107-25116
23. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 6797 (2000) 747-752
24. van d'Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
25. Boucharaba A., Serre C.M., Guglielmi J., et al. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 103 25 (2006) 9643-9648